Search our team at AdventHealth Research Institute
-
NCT05211895
D9075C00001: A Phase 3, Randomized, Double blind, Placebo controlled, Multicentre, International Study of Durvalumab and Domvanalimab (AB154) as Sequential Therapy in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive, Platinum-based Concurrent Chemoradiation Therapy (PACIFIC 8)
This study is currently enrolling.Associated Conditions: Lung CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThis study is being carried out in stage III NSCLC which cannot be removed by surgery. In this study, we will identify the effectiveness and safety of a possible treatment combination – durvalumab...
-
NCT04852887
A PHASE III CLINICAL TRIAL EVALUATING DE-ESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT OF STAGE I, HORMONE SENSITIVE, HER2-NEGATIVE,ONCOTYPE RECURRENCE SCORE d 18 BREAST CANCER
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaThis study is being done to answer the following question: Is treatment with hormonal therapy as good as the usual treatment of radiation and hormonal therapy in women with low-risk breast cancer who...
-
NCT04140526
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study.
This study is currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Clinical Cancer ResearchResearch Location: Celebration, FloridaThis is a research study to find out if an experimental drug called ONC-392 is safe and effective in cancer patients and how the drug is absorbed and processed in the body of patients with cancer. ONC...
-
NCT04245397
A Phase 1, Open-Label, Dose-Escalation with Expansion Study of SX-682 in Subjects with Myelodysplastic Syndrome Who Had Disease Progression or are Intolerant to Prior Therapy
This study is currently enrolling.Associated Conditions: Myelodysplastic SyndromeResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThis research study is studying an investigational immunotherapy called SX-682 as a possible treatment for Myelodysplastic Syndrome.
-
NCT04793958
A Randomized PHase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy
This study is currently enrolling.Associated Conditions: Colorectal CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThis is a study involving an investigational (experimental) drug called MRTX849, being developed by Mirati Therapeutics, Inc., which is the company that provides MRTX849 study drug and is funding and...
-
NCT04457596
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThis study is being done to answer the following question: Is the combination of T-DM1 and a newer drug tucatinib, better than usual treatment with T-DM1 alone at preventing your cancer from returning...
-
NCT04291612
Sentinel Lymph Node Endometrial Cancer Trial: A Prospective Multicenter International Single-Arm Observational Trial (SELECT)
This study is currently enrolling.Associated Conditions: Endometrial CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaWe are doing this study to find out how often your type of cancer comes back (recurs) after the standard treatment. We also want to see how often the standard treatment results in a buildup of fluid...
-
Pilot Feasibility Study of the Interplay between the Host Gut Microbiome and Efficacy of Treatment for Epithelial Ovarian Cancer Patients Receiving IMmunotherapy
This study is currently enrolling.Associated Conditions: Ovarian, Fallopian, or Primary Peritoneum CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThis research is being done to see if your gut microbiome (microorganisms that live in the gut) could help as a biomarker of clinical response to immunotherapy.
-
NCT04393285
A Phase II Study of Abemaciclib in Combination with Letrozole in Advanced, Recurrent or Metastatic Endometrioid Endometrial Cancer
This study is currently enrolling.Associated Conditions: Endometrial CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to find out if the combination of the drugs abemaciclib and letrozole is better or worse than usual approach for your type of cancer. The usual approach is defined as care...
-
NCT02954874
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with greater than or equal to 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) after Neoadjuvant Chemotherapy.
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to compare the usual approach (no more treatment or additional chemotherapy and radiation therapy after surgery or radiation therapy alone after surgery), with any effects...
-
NCT02215265
A Phase III Trial of Risk-Stratified, Reduced Intensity Adjuvant Treatment in Patients Undergoing Transoral Surgery for Human Papillomavarius (HPV)-Positive Oropharyngeal Cancer
This study is currently enrolling.Associated Conditions: Head and Neck CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThis study aims to identify the best way of treating orpharyngeal cancer that are caused by HPV. At the moment, cancers caused by HPV are treated like any other cancer in the Head and Neck and the...
-
NCT03959085
A Phase 3 Randomized Trial of INotuzumab Ozogamicin (IND#: 133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Clinical Cancer ResearchDisseminated B-Cell Lymphoblastic Lymphoma (B-LLy): The overall goal of this study is to determine the outcomes of subjects with disseminated B-LLy receiving High Risk B-cell Acute Lymphoblastic...